治疗老年人膀胱过度活动症
Treating overactive bladder in the elderly.
作者信息
Wagg Adrian
机构信息
Division of Geriatric Medicine, Department of Medicine, University of Alberta, Edmonton, AB.
出版信息
Can Urol Assoc J. 2011 Oct;5(5 Suppl 2):S149-51. doi: 10.5489/cuaj.11188.
Abstract
The prevalence of the overactive bladder (OAB) symptom complex increases with age. Older people also appear to experience more severe incontinence syndromes, including OAB, than their younger counterparts. Older patients are more likely than younger individuals to ask for medication for bladder problems and to require higher doses of medication. Conventional treatment for OAB with conservative and lifestyle measures in combination with antimuscarinic pharmacotherapy is effective in older people. Although there is a theoretical potential for cognitive impairment with antimuscarinic agents, the newer antimuscarinics are cognitively safe in cognitively intact older people.
摘要
膀胱过度活动症（OAB）症状复合体的患病率随年龄增长而增加。与年轻人群相比，老年人似乎也更容易出现包括OAB在内的更严重的失禁综合征。老年患者比年轻个体更有可能因膀胱问题寻求药物治疗，并且需要更高剂量的药物。采用保守和生活方式措施并结合抗毒蕈碱药物疗法对OAB进行的传统治疗在老年人中是有效的。尽管抗毒蕈碱药物理论上有导致认知障碍的可能性，但新型抗毒蕈碱药物在认知功能正常的老年人中在认知方面是安全的。
相似文献
1
Treating overactive bladder in the elderly.治疗老年人膀胱过度活动症
Can Urol Assoc J. 2011 Oct;5(5 Suppl 2):S149-51. doi: 10.5489/cuaj.11188.
2
Overactive bladder in the elderly: a guide to pharmacological management.老年人膀胱过度活动症：药物治疗指南
Drugs Aging. 2005;22(12):1013-28. doi: 10.2165/00002512-200522120-00003.
3
Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.老年膀胱过度活动症患者中抗毒蕈碱药物与认知障碍的相关性研究。
Int J Clin Pract. 2010 Aug;64(9):1279-86. doi: 10.1111/j.1742-1241.2010.02449.x. Epub 2010 Jun 7.
4
Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.坚持使用处方抗毒蕈碱药物治疗膀胱过度活动症：英国经验。
BJU Int. 2012 Dec;110(11):1767-74. doi: 10.1111/j.1464-410X.2012.11023.x. Epub 2012 Mar 12.
5
Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment.老年人对膀胱过度活动症抗毒蕈碱治疗相关副作用的偏好：一项离散选择实验
Drugs Aging. 2017 Aug;34(8):615-623. doi: 10.1007/s40266-017-0474-6.
6
Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.膀胱过度活动症患者的心血管发病率、心率和抗毒蕈碱药物的使用。
BJU Int. 2010 Jul;106(2):268-74. doi: 10.1111/j.1464-410X.2009.09073.x. Epub 2009 Nov 17.
7
Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder.2015年对《Beers标准》的更新对与膀胱过度活动症使用抗毒蕈碱药物潜在不适当使用相关的患病率和成本估计的影响。
Drugs Aging. 2017 Jul;34(7):535-543. doi: 10.1007/s40266-017-0464-8.
8
Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.联合药物治疗过度活动膀胱患者的疗效和安全性：快速证据评估。
Eur Urol. 2019 Dec;76(6):767-779. doi: 10.1016/j.eururo.2019.07.010. Epub 2019 Aug 13.
9
A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.一项关于老年起始用米拉贝隆与抗毒蕈碱药物的前瞻性研究：来自膀胱过度活动症满意度量表和其他工具的患者报告结局。
Neurourol Urodyn. 2018 Jan;37(1):177-185. doi: 10.1002/nau.23271. Epub 2017 Mar 31.
10
Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.非索罗定治疗老年患者膀胱过度活动症和急迫性尿失禁的疗效及安全性综述。
Drugs Aging. 2015 Feb;32(2):103-25. doi: 10.1007/s40266-014-0237-6.
引用本文的文献
1
Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?索利那新治疗膀胱功能障碍：是否存在痴呆或认知障碍的风险？
Braz J Med Biol Res. 2022 Jan 25;55:e11721. doi: 10.1590/1414-431X2021e11721. eCollection 2022.
2
Overactive Bladder in Frail Older Adults.衰弱老年人中的膀胱过度活动症。
Drugs Aging. 2020 Aug;37(8):559-565. doi: 10.1007/s40266-020-00777-8.
3
Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.米拉贝隆治疗膀胱过度活动症：高龄患者的安全性和疗效。
Clin Interv Aging. 2020 Apr 23;15:575-581. doi: 10.2147/CIA.S174402. eCollection 2020.
4
The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.米拉贝隆治疗尿急的疗效及联合治疗的潜在效用。
Ther Adv Urol. 2018 Jul 6;10(8):243-256. doi: 10.1177/1756287218781255. eCollection 2018 Aug.
5
How Beliefs About Bladder Dysfunction Among Health-Care Professionals Influence Clinical Practice Development: Perspectives of Allied Health Professionals, Nurses, and Managers.医疗保健专业人员对膀胱功能障碍的认知如何影响临床实践发展：联合健康专业人员、护士及管理人员的观点
Int J MS Care. 2017 Jul-Aug;19(4):191-198. doi: 10.7224/1537-2073.2016-006.
6
CUA guideline on adult overactive bladder.加拿大泌尿外科学会成人膀胱过度活动症指南
Can Urol Assoc J. 2017 May;11(5):E142-E173. doi: 10.5489/cuaj.4586. Epub 2017 May 9.
7
Caffeine as a Probable Factor for Increased Risk of OAB Development in Elderly People.咖啡因可能是老年人患膀胱过度活动症风险增加的一个因素。
Curr Urol. 2016 Oct;9(3):124-131. doi: 10.1159/000442866. Epub 2016 Sep 20.
8
Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.非索罗定治疗老年患者膀胱过度活动症和急迫性尿失禁的疗效及安全性综述。
Drugs Aging. 2015 Feb;32(2):103-25. doi: 10.1007/s40266-014-0237-6.
9
Mirabegron: a Beta-3 agonist for overactive bladder.米拉贝隆：一种用于治疗膀胱过度活动症的β-3受体激动剂。
Consult Pharm. 2014 Dec;29(12):823-37. doi: 10.4140/TCP.n.2014.823.
10
Use of onabotulinumtoxinA for overactive bladder with concomitant warfarin.A型肉毒杆菌毒素用于伴有华法林治疗的膀胱过度活动症。
Consult Pharm. 2014 Jul;29(7):480-6. doi: 10.4140/TCP.n.2014.480.
本文引用的文献
1
Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.特托罗定治疗老年和年轻膀胱过度活动症患者的疗效和耐受性。
Urology. 2010 Dec;76(6):1350-7. doi: 10.1016/j.urology.2010.03.097. Epub 2010 Oct 25.
2
Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder.氯化托品对记忆测试没有影响，在患有膀胱过度活动症的老年患者的中枢神经系统中无法检测到。
Int J Clin Pract. 2010 Aug;64(9):1294-300. doi: 10.1111/j.1742-1241.2010.02433.x. Epub 2010 Jun 17.
3
Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.老年膀胱过度活动症患者中抗毒蕈碱药物与认知障碍的相关性研究。
Int J Clin Pract. 2010 Aug;64(9):1279-86. doi: 10.1111/j.1742-1241.2010.02449.x. Epub 2010 Jun 7.
4
Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years.尿失禁、膀胱过度活动症和其他下尿路症状：45-103 岁男性的纵向基于人群的调查。
Eur Urol. 2010 Jul;58(1):149-56. doi: 10.1016/j.eururo.2010.03.014. Epub 2010 Mar 23.
5
Brain activity during bladder filling is related to white matter structural changes in older women with urinary incontinence.膀胱充盈时的大脑活动与老年女性尿失禁的白质结构变化有关。
Neuroimage. 2010 Jul 15;51(4):1294-302. doi: 10.1016/j.neuroimage.2010.03.016. Epub 2010 Mar 17.
6
Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.评估老年患者单次口服索利那新 10mg 后发生认知障碍或镇静风险的探索性临床试验
Expert Opin Drug Saf. 2009 Nov;8(6):615-26. doi: 10.1517/14740330903260790.
7
Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.老年普通人群中具有抗胆碱能特性的药物、认知功能减退与痴呆：三城市研究
Arch Intern Med. 2009 Jul 27;169(14):1317-24. doi: 10.1001/archinternmed.2009.229.
8
Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults.社区居住的老年人脑白质高信号与尿失禁的定位
J Gerontol A Biol Sci Med Sci. 2009 Aug;64(8):902-9. doi: 10.1093/gerona/glp037. Epub 2009 Apr 21.
9
Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence.口服缓释奥昔布宁对患有急迫性尿失禁的认知障碍养老院居民认知效果、安全性及耐受性的随机安慰剂对照试验
J Am Geriatr Soc. 2008 May;56(5):862-70. doi: 10.1111/j.1532-5415.2008.01680.x. Epub 2008 Apr 9.
10
Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.达非那新治疗65岁及以上膀胱过度活动症患者：一项随机、对照、为期12周试验的结果
Curr Med Res Opin. 2007 Oct;23(10):2347-58. doi: 10.1185/03007X226294.
Zotero 插件